Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Karolinska Development's portfolio company OssDsign raises SEK 150 million and makes strategic move to become a pure play orthobiologics...
Karolinska Development's portfolio company OssDsign has received FDA clearance for a new major indication STOCKHOLM, SWEDEN, September...
Interim Report - January-June 2023 STOCKHOLM – 25 August 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim...
Karolinska Development’s portfolio company Umecrine Cognition presents data on golexanolone in a preclinical model of Parkinson’s disease...
Karolinska Development’s portfolio company Umecrine Cognition presents data on golexanolone’s mode-of-action and ability to reduce...
Karolinska Development’s Annual General Meeting 2023 STOCKHOLM, SWEDEN – May 16, 2023. Karolinska Development AB (publ) (“Karolinska...
Karolinska Development's portfolio company Modus Therapeutics sees potential for its drug candidate sevuparin in the treatment of anemia...
Interim Report - January-March 2023 STOCKHOLM – 28 April 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim...
Karolinska Development’s portfolio company Umecrine Cognition includes first patient in Phase 2 study of golexanolon in primary biliary...
Karolinska Development’s portfolio company AnaCardio recruits first patient to a clinical trial of its drug candidate AC01 STOCKHOLM, SWEDEN...
Notice of Annual General Meeting in Karolinska Development AB (publ) The shareholders of Karolinska Development AB (publ), reg. no...
Karolinska Development’s portfolio company Umecrine Cognition secures additional funding for further development of golexanolone STOCKHOLM...
Karolinska Development Annual Report 2022 published STOCKHOLM, SWEDEN – March 24, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV...
Karolinska Development’s portfolio company AnaCardio’s founder publishes article that supports development of heart failure drug candidate AC01...
Karolinska Development’s portfolio company Biosergen presents positive results from phase 1 study of drug candidate to treat systemic fungal...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관